Intravenous angiotensin II attenuated the dynamic gain from vagal stimulation to heart rate from 7.6 to 5.8 beats/min/Hz (P<0.01) and from sympathetic stimulation from 10.8 to 10.2 (P=0.049).
Does intravenous angiotensin II alter the dynamic vagal and sympathetic regulation of heart rate in anesthetized rabbits?
Angiotensin II disproportionally suppresses dynamic vagal regulation compared to sympathetic regulation of heart rate, potentially explaining reduced high-frequency heart rate variability in cardiovascular diseases.
Absolute Event Rate: 5.8% vs 7.6%
p-value: p=<0.01
To better understand the pathophysiological role of angiotensin II (ANG II) in the dynamic autonomic regulation of heart rate (HR), we examined the effects of intravenous administration of ANG II (10 microg.kg(-1).h(-1)) on the transfer function from vagal or sympathetic nerve stimulation to HR in anesthetized rabbits with sinoaortic denervation and vagotomy. In the vagal stimulation group (n = 7), we stimulated the right vagal nerve for 10 min using binary white noise (0-10 Hz). The transfer function from vagal stimulation to HR approximated a first-order low-pass filter with pure delay. ANG II attenuated the dynamic gain from 7.6 +/- 0.9 to 5.8 +/- 0.9 beats.min(-1).Hz(-1) (means +/- SD; P < 0.01) without affecting the corner frequency or pure delay. In the sympathetic stimulation group (n = 7), we stimulated the right postganglionic cardiac sympathetic nerve for 20 min using binary white noise (0-5 Hz). The transfer function from sympathetic stimulation to HR approximated a second-order low-pass filter with pure delay. ANG II slightly attenuated the dynamic gain from 10.8 +/- 2.6 to 10.2 +/- 3.1 beats.min(-1).Hz(-1) (P = 0.049) without affecting the natural frequency, damping ratio, or pure delay. The disproportional suppression of the dynamic vagal and sympathetic regulation of HR would result in a relative sympathetic predominance in the presence of ANG II. The reduced high-frequency component of HR variability in patients with cardiovascular diseases, such as myocardial infarction and heart failure, may be explained in part by the peripheral effects of ANG II on the dynamic autonomic regulation of HR.
Kawada et al. (Sat,) conducted a other in sinoaortic denervation and vagotomy (n=14). Angiotensin II vs. Baseline was evaluated on Dynamic gain from vagal stimulation to heart rate (beats.min(-1).Hz(-1)) (p=<0.01). Intravenous angiotensin II attenuated the dynamic gain from vagal stimulation to heart rate from 7.6 to 5.8 beats/min/Hz (P<0.01) and from sympathetic stimulation from 10.8 to 10.2 (P=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: